prescription fees

Summary

Summary: The charge levied on the consumer for drugs or therapy prescribed under written order of a physician or other health professional.

Top Publications

  1. ncbi The cost of prescription medicines to patients
    P R Noyce
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester, UK
    Health Policy 52:129-45. 2000
  2. ncbi Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 346:822-9. 2002
  3. ncbi The effect of incentive-based formularies on prescription-drug utilization and spending
    Haiden A Huskamp
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 349:2224-32. 2003
  4. ncbi Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
    Med Care 42:653-60. 2004
  5. ncbi Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000
    Jennifer S Haas
    Brigham and Women s Hospital, Division of General Medicine and Primary Care, Boston, Massachusetts 02120, USA
    Ann Intern Med 142:891-7. 2005
  6. ncbi Prescription drug cost sharing: associations with medication and medical utilization and spending and health
    Dana P Goldman
    Health Economics, Finance, and Organization, RAND, Santa Monica, California 90407 2138, USA
    JAMA 298:61-9. 2007
  7. ncbi What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden
    Karolina Andersson
    Department of Social Medicine, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Pharmacoepidemiol Drug Saf 14:341-8. 2005
  8. ncbi Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence
    Joel Lexchin
    School of Health Policy and Management at York University, Toronto, Canada
    Int J Health Serv 34:101-22. 2004
  9. pmc Does knowledge of medication prices predict physicians' support for cost effective prescribing policies
    Jennifer M Polinski
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA, USA
    Can J Clin Pharmacol 15:e286-94. 2008
  10. ncbi A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures
    John D Piette
    VA Healthcare System and University of Michigan, Ann Arbor, MI, USA
    Soc Sci Med 62:846-57. 2006

Detail Information

Publications170 found, 100 shown here

  1. ncbi The cost of prescription medicines to patients
    P R Noyce
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester, UK
    Health Policy 52:129-45. 2000
    ..The method used in this study may also provide a route for investigating model systems prior to implementation...
  2. ncbi Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 346:822-9. 2002
    ..Although reference pricing may reduce the costs of prescription drugs, there is concern that patients may switch to less effective medications or stop treatment...
  3. ncbi The effect of incentive-based formularies on prescription-drug utilization and spending
    Haiden A Huskamp
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 349:2224-32. 2003
    ..Many employers and health plans have adopted incentive-based formularies in an attempt to control prescription-drug costs...
  4. ncbi Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents
    Sebastian Schneeweiss
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02120, USA
    Med Care 42:653-60. 2004
    ..Critics argued that drug plan savings are offset by administrative costs and increased spending on other health services...
  5. ncbi Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000
    Jennifer S Haas
    Brigham and Women s Hospital, Division of General Medicine and Primary Care, Boston, Massachusetts 02120, USA
    Ann Intern Med 142:891-7. 2005
    ..Generic substitution is one mechanism of curtailing prescription drug expenditures. Limited information is available about the potential savings associated with generic substitution...
  6. ncbi Prescription drug cost sharing: associations with medication and medical utilization and spending and health
    Dana P Goldman
    Health Economics, Finance, and Organization, RAND, Santa Monica, California 90407 2138, USA
    JAMA 298:61-9. 2007
    ..Prescription drugs are instrumental to managing and preventing chronic disease. Recent changes in US prescription drug cost sharing could affect access to them...
  7. ncbi What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden
    Karolina Andersson
    Department of Social Medicine, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Pharmacoepidemiol Drug Saf 14:341-8. 2005
    ..The aim of the present study was to investigate obstacles to generic substitution and savings achieved during the first year after Sweden introduced generic substitution in October 2002...
  8. ncbi Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence
    Joel Lexchin
    School of Health Policy and Management at York University, Toronto, Canada
    Int J Health Serv 34:101-22. 2004
    ..Cost sharing also leads to patients foregoing essential medications and to a decline in health care status...
  9. pmc Does knowledge of medication prices predict physicians' support for cost effective prescribing policies
    Jennifer M Polinski
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA, USA
    Can J Clin Pharmacol 15:e286-94. 2008
    ..Years after implementation, these policies remain controversial among physicians...
  10. ncbi A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures
    John D Piette
    VA Healthcare System and University of Michigan, Ann Arbor, MI, USA
    Soc Sci Med 62:846-57. 2006
    ..The next generation of studies examining the consequences of prescription drug costs should expand our knowledge of the ways in which these co-factors influence patients' responses to medication cost pressures...
  11. ncbi Promise and perils for patients and physicians
    Richard L Kravitz
    Center for Health Services Research in Primary Care, University of California, Davis, Calif, USA
    N Engl J Med 353:2735-9. 2005
  12. pmc Self-restriction of medications due to cost in seniors without prescription coverage
    M A Steinman
    Division of Geriatrics, San Francisco VA Medical Center, University of California San Francisco 94121, USA
    J Gen Intern Med 16:793-9. 2001
    ..We sought to identify which elderly patients are at highest risk of restricting their medications because of cost, and how prescription coverage modifies this risk...
  13. ncbi Effects of reaching the drug benefit threshold on Medicare members' healthcare utilization during the first year of Medicare Part D
    Marsha A Raebel
    Kaiser Permanente Colorado Institute for Health Research, Denver, Colorado 80237, USA
    Med Care 46:1116-22. 2008
    ..Information on the effects of reaching the Medicare Part D standard drug benefit threshold is limited...
  14. ncbi Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage
    Chien Wen Tseng
    University of Hawaii Department of Family Practice and Community Health, Honolulu, and UCLA Department of Medicine, Los Angeles, Calif
    JAMA 292:952-60. 2004
    ....
  15. ncbi A prescription for a modern Medicare program
    Peter B Bach
    Dr Bach is a senior adviser and Dr McClellan the administrator of the Centers for Medicare and Medicaid Services, Washington, D C
    N Engl J Med 353:2733-5. 2005
  16. ncbi Comparison of drug regimen costs between the Medicare prescription discount program and other purchasing systems
    John M Hayes
    JAMA 294:427-8. 2005
  17. ncbi Medicare-approved drug discount cards and renal transplant patients: how much can these cards reduce prescription costs?
    Marie A Chisholm
    University of Georgia College of Pharmacy, Augusta, GA 30912, USA
    Clin Transplant 19:357-63. 2005
    ..The purpose of this study was to determine whether enrolling renal transplant patients (RTPs) into a MADDC produces significant savings in prescription costs...
  18. ncbi Prior authorization and the formulary exception process--examples from the real world
    Eric J Culley
    J Manag Care Pharm 11:349-51. 2005
  19. ncbi The relationship between older adults' knowledge of their drug coverage and medication cost problems
    John D Piette
    Department of Veterans Affairs Center for Practice Management and Outcomes Research, Ann Arbor, Michigan 48113, USA
    J Am Geriatr Soc 54:91-6. 2006
    ..To determine whether chronically ill patients have gaps in knowledge about their prescription drug coverage and establish the relationship between gaps and medication cost problems...
  20. ncbi [Evaluation of accessibility to drugs for patients in the years 1996-2001]
    Mariola Drozd
    Zakładu Zarzqdzania i Ekonomiki Farmaceutycznej Akademii Medycznej w Lublinie
    Wiad Lek 55:651-4. 2002
    ..In consequence of these effects it was the diminution of the accessibility to the drugs by the patients on account of a growth of patient participation in the pharmacotherapy costs...
  21. ncbi Gap in drug coverage often causes lapses in adherence to drug regimen, study shows
    Deborah Levenson
    Rep Med Guidel Outcomes Res 15:9-10, 12. 2004
  22. ncbi How do seniors use their prescription drug discount cards?
    Cindy Parks Thomas
    Schneider Institutefor Health Policy, Brandeis University, Waltham, Massachusetts, USA
    Health Aff (Millwood) . 2005
    ..This suggests that some had other options or that more effort is needed to assure that seniors understand the value of drug savings programs and how to use them...
  23. ncbi When patients cannot afford their medications
    Chien Wen Tseng
    University of Hawaii, John A Burns School of Medicine, Dept of Family Medicine and Community Health, Mililani, USA
    Am Fam Physician 70:605-6, 608. 2004
  24. ncbi Incentive-based formularies
    Cindy Parks Thomas
    Heller School for Social Policy and Management, Brandeis University, Waltham, Mass, USA
    N Engl J Med 349:2186-8. 2003
  25. doi Tier 4 drugs and the fraying of the social compact
    Thomas H Lee
    Partners HealthCare System, Boston, USA
    N Engl J Med 359:333-5. 2008
  26. ncbi Medication cost-sharing: helping chronically ill patients cope
    John D Piette
    Med Care 43:947-50. 2005
  27. ncbi Perverse incentives in the Medicare prescription drug benefit
    David McAdams
    Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA 02142, USA
    Inquiry 44:157-66. 2007
    ..In particular, if all plans were required to charge the same premium, there would be less diversity in quality, but also less need to regulate formulary composition, less budgetary uncertainty, and less upward pressure on drug prices...
  28. ncbi Consumer response to dual incentives under multitiered prescription drug formularies
    Boyd H Gilman
    Mathematica Policy Research, Inc, Cambridge, MA 02139, USA
    Am J Manag Care 13:353-9. 2007
    ....
  29. ncbi Relationship between generic and preferred-brand prescription copayment differentials and generic fill rate
    Douglas E Mager
    Express Scripts, Inc, Maryland Heights, MO 63043, USA com
    Am J Manag Care 13:347-52. 2007
    ..To evaluate the relationship between generic and brand copayment differentials and generic fill rate (GFR)...
  30. ncbi The effect of insurance type on prescription drug use and expenditures among elderly Medicare beneficiaries
    Shadi S Saleh
    State University of New York at Albany, USA
    J Health Hum Serv Adm 30:50-74. 2007
    ..In conclusion, The differences in drug use and expenditures by insurance type imply that each party (Medicare, Medicare Advantage plans, employers) will have a different set of disincentives for involvement in Medicare Part D...
  31. ncbi Racial and ethnic disparities in the financial burden of prescription drugs among older Americans
    K Tom Xu
    School of Medicine, Texas Tech University Health Sciences Center, USA
    J Health Hum Serv Adm 30:28-49. 2007
    ..However, whether health disparities contribute to disparities in the financial burden of prescription drugs requires studies of specific diseases...
  32. doi Out-of-pocket costs to users: medicine options for hypertension
    Armando Arredondo
    Department for Health System Research, National Institute of Public Health, Cuernavaca, Morelos, Mexico
    Am J Hypertens 21:492. 2008
  33. ncbi Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans
    Uptal D Patel
    Duke University Medical Center, Box 3646, Division of Nephrology, Durham, NC 27710, USA
    J Am Soc Nephrol 17:2546-53. 2006
    ....
  34. ncbi Repackaged pharmaceuticals in the California workers' compensation system: from distribution and pricing options to physician and retail dispensing
    Matthew Gitlin
    Department of Clinical Pharmacy, University of California, San Francisco, USA
    Am J Ind Med 50:303-15. 2007
    ..In addition, we will determine what characteristics explain repackaged costs to identify reasons for repackaged pharmaceutical use...
  35. pmc Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states
    Matthew M Davis
    Division of General Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0456, USA
    J Gen Intern Med 22:257-63. 2007
    ..Variations in estimated PDP costs for beneficiaries living in different states have not previously been characterized...
  36. ncbi Experts' agency problems: evidence from the prescription drug market in Japan
    Toshiaki Iizuka
    Rand J Econ 38:844-62. 2007
    ..Overall, although the mark-up affects prescription choices, physicians appear more responsive to the patient's out-of-pocket costs than their own profits from mark-up...
  37. ncbi Medicare prescription drug cards: effectiveness for patients with glaucoma
    Ankit A Mahadevia
    School of Medicine and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21287, USA
    Arch Ophthalmol 124:1175-9. 2006
    ..To assess the level of discounts on glaucoma medications provided by the Medicare prescription drug card program...
  38. ncbi Savings from Canadian Internet pharmacies are limited
    Michael Rothberg
    Ann Intern Med 144:224; author reply 224-5. 2006
  39. ncbi Benefits and consequences for the poor and the disabled
    Rachel A Elliott
    University of Manchester, Manchester, United Kingdom
    N Engl J Med 353:2739-41. 2005
  40. ncbi The Medicare Part D drug benefit: lessons from the experience with drug discount cards
    Paul L Doering
    College of Pharmacy, University of Florida, Gainesville, FL 32611, USA
    Am J Geriatr Cardiol 14:308-12. 2005
    ..By carefully looking back on these hurdles, perhaps one can anticipate some of the problems that will likely be encountered when the full program is implemented and assist patients in realizing its maximum benefits...
  41. ncbi Controlling prescription drug expenditures: a report of success
    David P Miller
    General Internal Medicine, Wake Forest University Health Sciences, Winston Salem, NC 27157, USA
    Am J Manag Care 13:473-80. 2007
    ..To determine whether a multi-interventional program can limit increases in prescription drug expenditures while maintaining utilization of needed medications...
  42. ncbi Unraveling the effects of tier-copayment drug benefit designs
    Frederic R Curtiss
    J Manag Care Pharm 9:177-8. 2003
  43. ncbi Controlling spending for prescription drugs
    Stuart H Altman
    N Engl J Med 346:855-6. 2002
  44. ncbi The prescription-drug problem
    Robert Steinbrook
    N Engl J Med 346:790. 2002
  45. ncbi Initiatives to control drug costs associated with an independent physician association
    Paul Abourjaily
    Department of Pharmacy, Tufts New England Medical Center, 750 Washington Street, 420, Boston, MA 02111, USA
    Am J Health Syst Pharm 60:269-72. 2003
  46. ncbi Approaches to pharmacy benefit management and the impact of consumer cost sharing
    Bridget M Olson
    The University of Arizona, College of Pharmacy, Center for Health Outcomes and PharmacoEconomic Research, Tucson, Arizona 85721 0207, USA
    Clin Ther 25:250-72. 2003
    ..An understanding of the most prominent mechanisms of benefit management is an important step in determining the most effective approach to take in future years...
  47. ncbi Employer drug benefit plans and spending on prescription drugs
    Geoffrey F Joyce
    RAND Health, 1700 Main St, Santa Monica, CA 90407 2138, USA
    JAMA 288:1733-9. 2002
    ..It is unknown how these initiatives affect drug costs...
  48. ncbi Plastic price cuts? Drug discount cards shave but don't slash high bills. And most aren't free
    Avery Comarow
    US News World Rep 132:74-6. 2002
  49. ncbi Consider medicare drug benefit plan for healthcare reform
    Mark R Henschke
    J Am Osteopath Assoc 102:523-4. 2002
  50. ncbi Consumers devise drug cost-cutting measures: medical and legal issues to consider
    Gouranga Ganguli
    Department of Accounting and Business Law, 1201 W University Drive, University of Texas Pan American, Edinburgh, TX 78539, USA
    Health Care Manag (Frederick) 22:275-81. 2003
    ..The problem must receive prompt concerted attention from consumers, insurers, pharmaceutical companies, and lawmakers before it gets out of hand...
  51. ncbi Prescription drug benefits and health status among Medicare patients
    Richard Moldawsky
    JAMA 290:1994; author reply 1994-5. 2003
  52. ncbi Financial consequences of drug benefit plans
    John Hsu
    JAMA 289:423; author reply 424. 2003
  53. ncbi Financial consequences of drug benefit plans
    Bartholomew E Clark
    JAMA 289:423; author reply 424. 2003
  54. ncbi Pharmacy compliance with a prescription-drug discount program
    Katherine K Knapp
    N Engl J Med 347:146-7; author reply 146-7. 2002
  55. ncbi Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
    Andreas Maetzel
    University Health Network Research Institute, Toronto, Ontario, Canada
    Arthritis Rheum 47:655-61. 2002
    ....
  56. pmc The effects of the coverage gap on drug spending: a closer look at Medicare Part D
    Yuting Zhang
    Department of Health Policy and Management, University of Pittsburgh, Pennsylvania, USA
    Health Aff (Millwood) 28:w317-25. 2009
    ..Coverage of generic drugs with a $0-$10 copayment in the doughnut hole could be financed by, at most, a six-to-nine-percentage-point increase in initial coinsurance...
  57. ncbi How much 'skin in the game' do medicare beneficiaries have? The increasing financial burden of health care spending, 1997-2003
    Patricia Neuman
    Medicare Policy Project, Henry J Kaiser Family Foundation, Washington, DC, USA
    Health Aff (Millwood) 26:1692-701. 2007
    ..9 percent spent more than a fifth of their income on health care. Results suggest that sustained increases in out-of-pocket spending could make health care less affordable for all but the highest-income beneficiaries...
  58. ncbi Affordable medications in India
    Sunil Abraham
    Fam Pract Manag 13:16. 2006
  59. ncbi Adherence to medication under mandatory and voluntary mail benefit designs
    Joshua N Liberman
    Geisinger Health System, Center for Health Research, Danville, PA 17822 USA
    Am J Manag Care 17:e260-9. 2011
    ..To compare adherence rates under voluntary and mandatory mail benefit designs...
  60. ncbi Prescription-drug prices
    Richard G Frank
    Department of Health Care Policy, Harvard Medical School, Boston, USA
    N Engl J Med 351:1375-7. 2004
  61. ncbi Senate GOP tosses drug bill. Law would have let Medicare negotiate costs directly
    Matthew DoBias
    Mod Healthc 37:12. 2007
  62. ncbi Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients
    Chien Wen Tseng
    Department of Family Practice and Community Health, University of Hawaii, and Pacific Health Research Institute, Honolulu, USA
    JAMA 290:222-7. 2003
    ..Annual dollar limits, or "caps," on drug benefits are common in Medicare managed care (Medicare + Choice) and have been part of several proposals for a national Medicare drug benefit...
  63. ncbi Therapeutics, drug pricing and innovation
    J Somberg
    Am J Ther 10:381. 2003
  64. ncbi Effects of a monetary incentive on primary care prescribing in Ireland: changes in prescribing patterns in one health board 1990-1995
    T Walley
    Department of Pharmacology and Therapeutics, University of Liverpool, UK
    Pharmacoepidemiol Drug Saf 9:591-8. 2000
    ..In an attempt to curb the rapidly rising costs of primary care prescribing in Ireland, the government introduced a financial incentive scheme in 1993, to encourage general practitioners to restrain their prescribing...
  65. ncbi [Drug expenditures of pensioners in 1997-2000]
    Piotr Swistak
    Katedry i Zakładu Podstawowych Nauk Biomedycznych Wydziału Farmaceutycznego w Sosnowcu
    Wiad Lek 56:85-8. 2003
    ..93% units of reimbursed drugs in 2000. The possibility of buying drugs within OTC group increased by 18%...
  66. ncbi The cutaneous adverse drug reactions: risk factors, prognosis and economic impacts
    P J Liao
    Department of Health Care Administration, Oriental Institute of Technology, New Taipei City, Taiwan
    Int J Clin Pract 67:576-84. 2013
    ..The aim of this study was to explore the factors associated with the occurrence, subsequent prognoses and need for additional medications following cutaneous adverse drug reactions (ADRs) among inpatients...
  67. ncbi The HIV pharmacy: managing quality and costs of HIV care
    William M Valenti
    University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    AIDS Read 12:486-8. 2002
  68. ncbi Gift giving
    Robert R Raszkowski
    S D J Med 55:513-4. 2002
  69. pmc The new Medicare Part D prescription drug benefit: an estimation of its effect on prescription drug costs in a Medicare population with atrial fibrillation
    Carmella Evans-Molina
    Department of Medicine, Division of Endocrinology and Metabolism, University of Virginia, Charlottesville, Virginia, USA
    J Am Geriatr Soc 55:1038-43. 2007
    ..To compare prescription drug cost savings under the most commonly selected Medicare Part D prescription plan in 2006 with savings under the Medicare standard benefit and with drug costs assuming no coverage in an elderly cohort of patients...
  70. pmc Barriers to and facilitators of antiretroviral therapy adherence in Nepal: a qualitative study
    Sharada P Wasti
    School of Health and Related Research ScHARR, University of Sheffield, Sheffield, UK
    J Health Popul Nutr 30:410-9. 2012
    ..Healthcare providers should address some of the practical and cultural issues around ART whilst policy-makers should develop appropriate social policy to promote adherence among ART-prescribed patients...
  71. pmc Beneficiaries with cardiovascular disease and thePart D coverage gap
    Jennifer M Polinski
    Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Boston, MA 02120, USA
    Circ Cardiovasc Qual Outcomes 5:387-95. 2012
    ..The coverage gap remains the subject of Congressional debate; evidence regarding its impact on cardiovascular drug use and health outcomes is needed...
  72. ncbi Ensuring fairness in coverage decisions: applying the American Medical Association Ethical Force Program's consensus report to managed care pharmacy
    J Russell Teagarden
    Clinical Practices and Therapeutics, Medco Health Solutions, Inc, 100 Parsons Pond Drive, Franklin Lakes, NJ 07417, USA
    Am J Health Syst Pharm 63:1749-54. 2006
  73. ncbi Effect of copayments on drug use in the presence of annual payment limits
    George Kephart
    Department of Community Health and Epidemiology, Dalhousie University, Halifax, NS, Canada
    Am J Manag Care 13:328-34. 2007
    ....
  74. ncbi Patient cost associated with filling a prescription for extended-duration venous thromboembolism (VTE) prophylaxis following surgery for gynecologic cancer
    Katherine Cain
    Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 127:18-21. 2012
    ..The primary purpose of this study was to determine the average patient cost for filling a prescription for extended-duration enoxaparin prophylaxis...
  75. ncbi Medication costs: the role physicians play with their senior patients
    Mary Sue Beran
    Park Nicollet Institute, Health Research Center, Minneapolis, MN 55416, USA
    J Am Geriatr Soc 55:102-7. 2007
    ..To determine how often primary care physicians discuss medication costs with their senior patients and what cost-reducing strategies they employ...
  76. ncbi Tips for preparing for a 340B integrity audit
    William Wood
    Visante Inc, Eden Prairie, Minn, USA
    Healthc Financ Manage 66:50-2. 2012
    ..Develop policies and procedures that specifically address the issues of patient eligibility, duplicate discounts, and appropriate Medicaid billing. Create a multidisciplinary team for 340B program oversight...
  77. ncbi [Incidence, resource use and costs associated with postherpetic neuralgia: a population-based retrospective study]
    Antonio Sicras-Mainar
    Dirección de Planificación y Desarrollo Organizativo, Badalona, Espana
    Rev Neurol 55:449-61. 2012
    ..To determine the incidence rate, the treatment administered and the use of health resources and health, and their respective costs in patients with postherpetic neuralgia (PHN)...
  78. ncbi [Real per capita health spending by age and sex in Spain (1998-2008): changes and effects on public healthcare expenditure projections]
    Angela Blanco Moreno
    DG SANCO, Comisión Europea, Bruselas, Belgica
    Gac Sanit 27:220-5. 2013
    ..To analyze changes in real per capita spending by age and sex from 1998 to 2008 in Spain, and to assess their effects on public healthcare expenditure projections...
  79. pmc Evaluating linkage to care for hypertension after community-based screening in rural Uganda
    Prashant Kotwani
    Division of HIV AIDS, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA Makerere University University of California San Francisco Research Collaboration, Mbarara, Kampala, Uganda
    Trop Med Int Health 19:459-68. 2014
    ..To determine the frequency and predictors of hypertension linkage to care after implementation of a linkage intervention in rural Uganda...
  80. ncbi Determination of the frequency and direct cost of the adverse drug events in Argentina
    Estela Izquierdo
    Clinical Pharmacy Unit, Department of Pharmaceutical Technology, University of Buenos Aires, Junin 956 1113, Buenos Aires, Argentina
    Curr Drug Saf 4:103-6. 2009
    ..Moderate and severe reactions were included regardless of the important indirect costs, hospitalization costs, tests, physician fees, etc...
  81. ncbi Comparison of prescription reimbursement methodologies in Japan and the United States
    Eiichi Akaho
    Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Nishi ku, Kobe, Japan
    J Am Pharm Assoc (2003) 43:519-26. 2003
    ..To compare methods of prescription reimbursement in Japan and the United States...
  82. ncbi Cost evaluation of risperidone compared with olanzapine
    Matthew J Byerly
    Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5959 Harry Hines Boulevard, Professional Office Building 1, Suite 600, Dallas, TX 75390 9101, USA
    Psychiatr Serv 54:742-4. 2003
    ..Although both treatments were associated with similar reductions in costs of psychiatric inpatient and outpatient care, it was significantly less expensive to prescribe risperidone than olanzapine...
  83. ncbi Doctors v. government--who cares most?
    Chris Bateman
    S Afr Med J 94:410-1. 2004
  84. ncbi Impact of a pharmacist consult clinic on a hospital-based geriatric outpatient clinic in Singapore
    W S Lim
    Department of Geriatric Medicine, Tan Tock Seng Hospital, Singapore
    Ann Acad Med Singapore 33:220-7. 2004
    ....
  85. ncbi Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs
    Kathleen A Fairman
    Express Scripts, Inc, Maryland Heights, Missouri 63043, USA
    Clin Ther 25:3147-61; discussion 3144-6. 2003
    ..Assessment of such systems with a longer follow-up period has been needed...
  86. ncbi Impact of the National Health Fund policy on hormone treatment for prostate cancer in Jamaica
    Belinda F Morrison
    Department of Surgery, University of the West Indies, Kingston, Jamaica
    Rev Panam Salud Publica 29:404-8. 2011
    ..To compare the proportion of patients choosing surgical versus medical castration to treat prostate cancer, before and after the National Health Fund (NHF) of Jamaica began to subsidize hormone therapy...
  87. ncbi Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V
    Jack M Mycka
    MME LLC, Montclair, NJ 07042, USA
    Value Health 13:25-7. 2010
    ..The objective of this report is to provide guidance and recommendations on how manufacturers should approach the use of drug costs...
  88. ncbi Prescription drug costs as a reason for changing physicians
    F A Lederle
    Department of Medicine, Minneapolis Veterans Affairs Medical Center, University of Minnesota 55417
    J Gen Intern Med 9:162-3. 1994
    ..001). Drug costs are a principal reason for patients to transfer their health care to the VA...
  89. ncbi Preferences for new and existing contraceptive products
    Denzil G Fiebig
    School of Economics, University of New South Wales, Sydney, Australia
    Health Econ 20:35-52. 2011
    ..The model forecasts that the hormonal patch would be well received among women, achieving a greater market share than current non-pill products, but the vaginal ring would have limited appeal...
  90. pmc Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality
    Montserrat Vera-Llonch
    Policy Analysis Inc PAI, Brookline, MA, USA
    BMC Cancer 11:250. 2011
    ..In this study, we characterize healthcare utilization and costs in the US among women with metastatic breast cancer receiving chemotherapy as their principal treatment modality...
  91. ncbi Financial consequences of drug benefit plans
    Brenda Motheral
    JAMA 289:423-4; author reply 424. 2003
  92. ncbi Linezolid: the first oxazolidinone antimicrobial
    D A Lindley
    Ann Intern Med 139:863; author reply 864. 2003
  93. ncbi Frequency and predictors of drug therapy interruptions after hospital discharge under physician drug budgets in Germany
    K Taxis
    Pharmazeutische Biologie, Pharmazeutisches Institut, Universitat Tubingen, Germany
    Int J Clin Pharmacol Ther 41:77-82. 2003
    ..We sought to study how frequently prescription drug therapy at hospital discharge was discontinued or changed by general practitioners under physician drug budgets in Germany and explore reasons and predictors for such discontinuations...
  94. ncbi Why did drug spending increase during the 1990s? A decomposition based on Swedish data
    Ulf G Gerdtham
    Department of Community Medicine, Malmo University Hospital, Lund University, Malmo, Sweden
    Pharmacoeconomics 22:29-42. 2004
    ..This paper updates a previous study, which looked at the period 1990-1995, by providing an additional 5 years of data (1995-2000) and extending the previous analysis in a number of ways...
  95. ncbi Current and future forecasts of service use and expenditures of Medicaid-eligible schizophrenia patients in the state of Georgia
    L Stephen Miller
    Department of Psychology, University of Arkansas for Medical Sciences, Little Rock, USA
    Schizophr Bull 30:983-95. 2004
    ..Trends include a significant increase in prescription expenditures over time concurrent with decreases in inpatient expenditures and relatively stable changes in community mental health center expenditures...
  96. ncbi Increasing pharmaceutical copayments: impact on asthma medication utilization and outcomes
    Jonathan D Campbell
    Universit of Colorado, School of Pharmacy, Aurora, CO 80045, USA
    Am J Manag Care 17:703-10. 2011
    ..The objective was to determine the impact of increasing patient prescription copayments for guideline recommended, long-term asthma controller (LTC) medications on asthma-related medication use and healthcare services...
  97. ncbi [Survey of tumor necrosis factor inhibitors application in patients with rheumatoid arthritis in China]
    Xiu ru Wang
    Department of Rheumatology and Immunology, Peking University People s Hospital, Beijing 100044, China
    Beijing Da Xue Xue Bao 44:182-7. 2012
    ..To investigate the current status of tumor necrosis factor (TNF) inhibitors application in rheumatoid arthritis (RA) patients in China and to analyze the related factors...
  98. ncbi Estimating medical costs of work-related diseases in the Basque Country (2008)
    Montserrat García Gómez
    Ministry of Health, Social Services and Equality Madrid, Spain
    Med Lav 104:267-76. 2013
    ..To estimate the medical costs of work-attributable diseases (WAD) treated by the public health care system for one of the Spanish Autonomous Communities, the Basque Country, in 2008...
  99. ncbi Has the European union achieved a single pharmaceutical market?
    Aysegul Timur
    Hodges University, Naples, FL, USA
    Int J Health Care Finance Econ 11:223-44. 2011
    ..We interpret this as evidence that the EU has come closer to achieving a single pharmaceutical market in response to increasing European Commission coordination efforts...
  100. ncbi Dronedarone for atrial fibrillation: How does it compare with amiodarone?
    Neelima Penugonda
    Department of Internal Medicine, Lankenau Hospital, Wynnewood, PA 19096, USA
    Cleve Clin J Med 78:179-85. 2011
    ....
  101. pmc Enhancing prescription drug innovation and adoption
    G Caleb Alexander
    University of Chicago Hospitals, University of Chicago, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Ann Intern Med 154:833-7, W-301. 2011
    ..Despite the challenges of policy implementation, the United States has a long history of successfully improving the societal value and safe use of prescription medicines...

Research Grants29

  1. Effects of Mental Parity on High-Cost and Severely-Ill Individuals
    Haiden A Huskamp; Fiscal Year: 2011
    ..We will estimate a combination of two-part random-effects models for longitudinal data, latent class random-effects models, logistic regression models, Poisson regression models, and hazard models to address these aims. ..
  2. Economics of Formulary Design and Mental Health Policy
    Haiden Huskamp; Fiscal Year: 2006
    ..Huskamp the training, mentoring, time and resources to develop the skills that will put her in a position to lead independent research on the economics of pharmaceutical treatment for mental illnesses. ..
  3. Impact of Medicaid Prescription Copayments in Patients with Schizophrenia
    Jalpa Doshi; Fiscal Year: 2009
    ..The findings of our study will help inform policymakers about the intended and unintended consequences of prescription copayments in Medicaid patients with schizophrenia. ..
  4. Racial Segregation & Disparities in Cancer Outcomes
    Jennifer Haas; Fiscal Year: 2007
    ..The proposed study would provide empirical evidence that could give impetus to area-based interventions to reduce cancer disparities. ..
  5. OLD AGE LONGEVITY AND THE MARKET FOR LONG TERM CARE
    Tomas Philipson; Fiscal Year: 2001
    ..Preliminary analysis of a subpart of the data that is to be collected more fully suggest that long-tenn care output contracts with male aging as predicted. ..
  6. MH AND ADVERSE SELECTION IN MANAGED CARE
    Thomas McGuire; Fiscal Year: 2001
    ..Understanding how adverse selection works in managed care and what can be done about it should be a very high priority for research. ..
  7. Using MEPS Data to Inform Public-Plan Consumerism
    Matthew Davis; Fiscal Year: 2007
    ..Findings will have immediate relevance for implementation of the HOA projects and other consumerism efforts. [unreadable] [unreadable] [unreadable]..
  8. Cancer in Older Minority Populations
    Alfred Neugut; Fiscal Year: 2003
    ..Coordination of this P20 will be facilitated by the geographic proximity of the two institutions, their scientific strengths, and their commitment to similar programs. ..
  9. MATERNAL HEALTH STATUS AND ADVERSE BIRTH OUTCOMES
    Jennifer Haas; Fiscal Year: 2002
    ..Such interventions should begin from the premise that improved maternal and infant outcomes can only come from improved maternal health. ..
  10. Computerized EMR-Assisted Smoking Cessation (CEASCE)
    Jennifer Haas; Fiscal Year: 2007
    ..Future Directions: Evaluate whether CEASCE can serve as a prototype for other common primary care problems that require counseling for behavior change. [unreadable] [unreadable]..
  11. Diabetes and Drug-Associated Hyperkalemia: Effect of Laboratory Monitoring
    Marsha Raebel; Fiscal Year: 2008
    ..The findings will also assist in developing a framework for future studies to evaluate the effects and costs of medication-laboratory monitoring among patients with diabetes. [unreadable] [unreadable] [unreadable] [unreadable]..
  12. NETWORK EFFECTS IN MENTAL HEALTH MANAGED CARE
    Thomas McGuire; Fiscal Year: 2002
    ..4) Test the behavior of the managed care plans against the predictions of the optimal network theory. ..
  13. Hurricane Katrina Community Advisory Group
    Ronald C Kessler; Fiscal Year: 2010
    ....
  14. Financial Incentives and Variations in the Care of Medicare Beneficiaries
    Bruce E Landon; Fiscal Year: 2010
    ..Because patients will be clustered within physicians and physicians clustered within markets, we will use hierarchical analytic methods. ..
  15. Mental Health Spending and Quality of Care
    Thomas G McGuire; Fiscal Year: 2010
    ..We expand methods of the science of variations and apply them to mental health care using data from the Medicaid program. ..
  16. Coding Audiotapes of Clinic Visits for Adherence Content
    Ira Wilson; Fiscal Year: 2006
    ..While this work focuses on adherence with ARVs for HIV disease, the GMIAS has been designed to be easily generalizable to other conditions and research problems in MD-PT communication. [unreadable] [unreadable]..
  17. Quantifying the Value of Value-Based Purchasing
    Ronald Kessler; Fiscal Year: 2006
    ..abstract_text> ..
  18. MD Group Characteristics and Quality of Care for CHD
    Bruce Landon; Fiscal Year: 2003
    ..abstract_text> ..
  19. CAREER DEVELOPMENT AWARD IN PEDIATRIC PSYCHOPHARMACOLOGY
    Andres Martin; Fiscal Year: 2004
    ..abstract_text> ..
  20. COLORECTAL CANCER AND OTHER CANCERS OF THE GI TRACT
    Alfred Neugut; Fiscal Year: 2005
    ..abstract_text> ..
  21. Life Cycle Effects of Health Insurance on Elderly Health
    Jalpa Doshi; Fiscal Year: 2006
    ..We will use these estimates to simulate the effect of changes in the age of Medicare eligibility on health, medical service use and Medicare expenditure. ..
  22. Outreach and Treatment for Depression in the Labor Force
    Ronald Kessler; Fiscal Year: 2005
    ..This is an extremely important opportunity for rapid and widespread dissemination in an area of research where dissemination of positive results has traditionally been a serious problem. ..
  23. MENTORED PATIENT-ORIENTED RESEARCH CAREER DEVELOPMENT
    Matthew Byerly; Fiscal Year: 2006
    ..abstract_text> ..
  24. Assessment of Growth Horomone Use in Short Children
    Leona Cuttler; Fiscal Year: 2008
    ..Moreover, the knowledge gained on determinants of treatment use will likely be applicable to many emerging therapies that have ambiguous beginnings and endings, but are highly valued by patients. ..
  25. Economics of Racial & Ethnic Disparities in MH Services
    Thomas McGuire; Fiscal Year: 2005
    ..Test for evidence that patient reaction to provider discrimination leads to lower compliance rates and worse outcomes for these minorities. ..
  26. MENTAL DISORDERS AS RISK FACTORS FOR SUBSTANCE DISORDERS
    Ronald Kessler; Fiscal Year: 2003
    ....
  27. Intervention for Stroke Survivors and Spousal Caregivers
    Sharon Ostwald; Fiscal Year: 2005
    ..Depending on the nature of the change function, individual parameter estimates of the intercept, slope, and if necessary, curvature will be compared across groups. ..
  28. Risk Factors for Psychopathology in the WHO WMH Surveys
    Ronald Kessler; Fiscal Year: 2009
    ..Third, the level of detail in the description of data analysis plans has been substantially expanded in this revised submission in response to reviewer comments. ..